Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Background MYD88 L265P and CXCR4WHIM mutations are highly prevalent in
Waldenström's macroglobulinemia. MYD88L265P triggers tumor-cell growth through …

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with
ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and …

Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary
course of cancer. Chronic lymphocytic leukaemia (CLL) is a highly informative model for …

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely
to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted …